Company Filing History:
2 out of 87 
2 out of 2,619 
1 out of 6 Years Active: 2015-2025
Title: Mi Jeong Kim: Innovator in Anti-Angiopoietin-2 Antibodies
Introduction
Mi Jeong Kim is a prominent inventor based in Daejeon, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target angiopoietin-2. With a total of three patents to her name, her work has the potential to impact various medical conditions associated with abnormal blood vessels.
Latest Patents
One of her latest patents focuses on anti-angiopoietin-2 antibodies that induce Tie2 activation. This invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2) and includes humanized anti-Ang2 antibodies derived from them. The anti-Ang2 antibodies possess a dual function of activating the Tie2 receptor while neutralizing Ang2. These antibodies are designed to normalize abnormal and pathological blood vessels, demonstrating therapeutic efficacy against various diseases and disorders linked to such conditions. Additionally, the invention provides an angiogenesis inhibitor and a composition for treating diseases associated with abnormal Ang2 expression and Tie2 dysregulation, which includes the antibody as an active ingredient.
Career Highlights
Mi Jeong Kim has worked at notable institutions such as the Institute for Basic Science and the Korea Advanced Institute of Science and Technology. Her research has been pivotal in advancing the understanding of angiogenesis and its implications in health and disease.
Collaborations
Throughout her career, Mi Jeong Kim has collaborated with esteemed colleagues, including Gou Young Koh and Jeomil Bae. These partnerships have contributed to the success of her research and the development of innovative solutions in her field.
Conclusion
Mi Jeong Kim's work in the development of anti-angiopoietin-2 antibodies showcases her dedication to advancing medical science. Her innovative contributions have the potential to lead to significant therapeutic advancements in treating diseases associated with abnormal blood vessels.